Ulcerative colitis — supplement adjuncts to standard therapy
In ulcerative colitis, 5-ASA agents (mesalamine), corticosteroids for induction, immunomodulators, and biologics (anti-TNF, anti-integrin, anti-IL-23, JAK inhibitors) are the disease-modifying therapies. A small set of supplements has credible adjunctive RCT evidence — bioavailable curcumin for both induction and maintenance, VSL#3/Visbiome for pouchitis and possibly maintenance, and omega-3 with mixed signal. Several common "gut healing" supplements are inappropriate in active UC.
The supplement layer with credible evidence
Curcumin (bioavailable form)
2–3 g/day curcuminoids (bioavailable formulation: Meriva, Theracurmin, BCM-95)
Multiple RCTs (Lang 2015, Kedia 2017, Hanai 2006) of curcumin in UC have shown clinical remission, mucosal healing, and reduced relapse rates as adjunct to 5-ASA at doses of 2–3 g/day curcuminoids for 8–12 weeks (induction) or 6 months (maintenance). Effect is modest but consistent across heterogeneous trials. Bioavailable formulations are the trial-tested versions. Discuss with gastroenterologist; theoretical anticoagulant interaction at high doses.
VSL#3 / Visbiome (8-strain high-CFU probiotic)
450 billion CFU/day (1–2 sachets) for maintenance
The VSL#3 formulation (now sold as Visbiome under the original manufacturer; the VSL#3 trademark is now a different product, which is a clinically relevant trial-vs-product confusion) has the strongest probiotic evidence in IBD. Multiple RCTs show maintenance of remission in pouchitis (post-colectomy ileal pouch inflammation), and a more modest signal in mild-moderate UC maintenance. The dose is high (the equivalent of multiple commercial probiotic capsules per day). Cost is significant; the trial-tested product specifically is Visbiome.
Marine omega-3 (EPA/DHA)
2.5–4 g/day EPA+DHA
Older trials showed promising induction signal in UC; the EPIC trials in Crohn's disease were negative; UC-specific meta-analyses are mixed. Reasonable adjunct for cardiovascular and inflammatory baseline; not a UC-specific intervention with strong evidence. Avoid if active GI bleeding.
Vitamin D3 (test and replete)
1,000–2,000 IU/day to maintain 25-OH-D 30–50 ng/mL
Low vitamin D is extremely common in IBD and observationally correlates with relapse risk. Trial evidence for disease-modifying effect is modest but skeletal-health rationale is strong (chronic corticosteroid exposure, malabsorption). Test and treat to a normal range.
Iron (only if iron-deficient)
Iron status guides dose; oral or IV per gastroenterologist
Iron deficiency is highly prevalent in UC (chronic blood loss + inflammatory-mediated absorption reduction). Oral ferrous bisglycinate is better tolerated than ferrous sulfate in IBD. In active inflammation or with poor oral tolerance, IV iron carboxymaltose or sucrose is preferred and gastroenterology-directed. Do not chase iron in active flare without GI input — oral iron can exacerbate symptoms in some patients.
Aloe vera (oral, decolorized)
200 mL twice daily of decolorized aloe gel
A single small RCT (Langmead 2004) showed modest improvement in mild-moderate active UC on aloe gel; not widely replicated. Reasonable optional adjunct in mild UC if other adjuncts are not preferred. Use decolorized (low-anthraquinone) preparations; the anthraquinone-containing aloe latex is a stimulant laxative inappropriate in UC.
What to skip
- Slippery elm, marshmallow root, DGL "leaky gut" stacks during active UC — minimal trial evidence in UC, fiber content can worsen symptoms during active flare.
- Cat's claw, echinacea, astragalus, AHCC — immune-stimulants inappropriate in autoimmune-driven IBD.
- High-dose vitamin C "for healing" — minimal trial evidence; high doses are osmotically active and can worsen diarrhea.
- Curcumin gum, "raw turmeric" powders at low doses — bioavailability is the limiting factor; consumer turmeric does not reach trial doses.
- "Gut healing" colostrum at high doses — case reports of UC flare; trial evidence is thin.
- Stopping 5-ASA "because I feel fine" — UC maintenance with 5-ASA reduces both relapse and colon-cancer risk. The decision to stop, narrow, or step down is gastroenterology-directed.
- Cannabinoids as primary treatment — symptom-modifying signal but does not alter inflammation; may obscure flare detection.
- Restrictive elimination diets without dietitian guidance — nutritional deficiency is a real risk; specific evidence-based protocols (UC-specific exclusion diets, low-FODMAP for symptom overlap with IBS) belong with an IBD dietitian.
The non-supplement layer that matters more
Mesalamine adherence (oral plus rectal where applicable — rectal mesalamine is dramatically underused), biologic therapy escalation when needed, smoking status (notably, smoking is protective against UC but harmful in every other way; never start smoking for UC, but the relationship matters), colorectal cancer surveillance colonoscopies, vaccination (live vaccines avoided on biologics; influenza/COVID/pneumococcal indicated), and stress management. Diet is increasingly trial-supported: Mediterranean and UC-specific exclusion diets in remission, low-residue or specific carbohydrate approaches during flare under dietitian guidance.